000			03951cam a2200421Mi 4500
001			ocn953657042
003			OCoLC
005			20240726104734.0
008			160716s2015 xx ob 001 0 eng d
040			_aEBLCP _beng _epn _erda _cEBLCP _dOCLCQ _dCCO _dOCLCO _dCOCUF _dLOA _dK6U _dOCLCF _dSTF _dPIFAG _dFVL _dMERUC _dOCLCQ _dZCU _dU3W _dWRM _dICG _dOCLCQ _dVT2 _dOCLCQ _dTKN _dDKC _dOCLCQ _dUKAHL _dOCLCQ _dNT
066			_cZsym _c(S
020			_a9781681081403 _q((electronic)l(electronic)ctronic)
050	0	4	_aQR177 _b.C435 2015
049			_aMAIN
100	1		_aManuela, Oliveira. _e1
245	1	0	_aThe challenges of antibiotic resistance in the development of new therapeutics.
260			_aSharjah : _bBentham Science Publishers, _c(c)2015.
300			_a1 online resource (279 pages)
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_adata file _2rda
490	1		_aFrontiers in Antimicrobial Agents ; _vv. 1
505	0	0	_6880-01 _aFOREWORD ; PREFACE ; List of Contributors ; Introduction ; INTRODUCTION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Bacteriophages as Antibacterial Agents: Why are We Facing an Antibiotic Crisis and How Could Bacteriophages be of Help? ; 1. INTRODUCTION; 2. WHY ARE WE FACING AN ANTIBIOTIC (AB) CRISIS? ; 3. HOW TO RESOLVE THIS ANTIBIOTIC CRISIS? ; 4. BACTERIOPHAGES OR IN SHORT 'PHAGES'; 5. BACTERIOPHAGE THERAPY OR PHAGE THERAPY; 6. EXPERIMENTAL PHAGE THERAPY; 7. SAFETY ISSUES; 8. IN FACT WE LIVE IN AN "OCEAN" OF BACTERIOPHAGES; 9. SAFETY REQUIREMENTS FOR PHAGE THERAPY.
505	0	0	_a10. THE POTENTIAL ADVANTAGES OF PHAGE THERAPY VERSUS ANTIBIOTICS11. PHAGE THERAPY IN PUBLIC HEALTH; 12. WHY PHAGE THERAPY IS NOT YET IMPLEMENTED?; CONCLUSIONS AND PERSPECTIVES; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Antimicrobial Peptides ; INTRODUCTION; 1. WHAT ARE ANTIMICROBIAL PEPTIDES (AMPS); 1.1. Mode of Action; 1.2. Immune System; 1.3. Resistance; 2. CHRONOLOGY OF AMPS DISCOVERY -- _tA BRIEF HISTORY; 2.1. Classification of AMPs; 2.1.1. Biological Source; 2.1.2. Biological Functions; 2.1.3. Biosynthesis; 2.1.4. Molecular Properties; 2.1.5. Molecular Targets.
505	0	0	_a2.1.6. Three-Dimensional (3D) Structure2.2. Currently Active AMPs Databases; 3. THERAPEUTIC APPLICATIONS OF AMPS; 3.1. Anticancer AMPs; 3.2. Antiviral AMPs; 3.3. Anti-parasitic AMPs; 3.4. New Generation of AMPs; CONCLUDING REMARKS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Probiotics: Ways of Action and Beneficial Effects ; 1. INTRODUCTION; 2. SELECTION OF PROBIOTICS; 3. COMMERCIALLY IMPORTANT PROBIOTICS; 4. MECHANISMS OF ACTION OF PROBIOTICS; 4.1. Immunomodulation; 4.2. Direct Effects on Other Microorganisms; 5. BENEFICIAL HEALTH EFFECTS OF PROBIOTICS.
505	0	0	_a5.1. Alleviation of Lactose Intolerance5.2. Effect on Helicobacter Pylori Eradication ; 5.3. Anti-carcinogenic Effect; 5.4. Cholesterol-lowering Effects; 5.5. Allergy and Atopic Dermatitis; 5.6. Inflammatory Diseases and Bowel Syndromes ; CONCLUSION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Immunotherapy ; 1. BACTERIAL INFECTIVITY, IMMUNE RESPONSE AND MULTIRESISTANT INFECTIONS : NEW PERSPECTIVES; 1.1. Introduction; 1.2. Host Resistance; 1.3. Bacterial Strategies for Evading, Surviving Host Defense Systems and Create Infection; 2. IMMUNOTHERAPY; 2.1. Introduction.
500			_a2.10.2. Propionibacterium Acnes.
504			_a1 at the end of each chapters and index.
530			_a2 _ub
650		0	_aDrug resistance in microorganisms.
655		1	_aElectronic Books.
700	1		_aSerrano, Isa D.
856	4	0	_zClick to access digital title | log in using your CIU ID number and my.ciu.edu password. _uhttpss://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=1108996&site=eds-live&custid=s3260518
942			_cOB _D _eEB _hQR _m2015 _QOL _R _x _8NFIC _2LOC
994			_a92 _bNT
999			_c76667 _d76667
902			_a1 _bCynthia Snell _c1 _dCynthia Snell